Canada approves Prochymal for GvHD

Health Canada granted conditional approval to Prochymal from Osiris Therapeutics Inc. (NASDAQ:OSIR) to treat acute graft-versus-host disease (GvHD) in children. Osiris is required to conduct a confirm...